Issue description:
ABFEs can overestimate binding affinities when the apo state is not adequately sampled on accessible simulation timescales. This limitation shows up in several related ways and could be discussed either as a standalone section or distributed across the existing water-network, conformational sampling, and cofactor sections.
The main cases to cover are:
Water resolvation in occluded pockets: In some systems, water does not re-enter the binding site during non-interacting alchemical windows, which can bias ABFEs toward overestimation. A possible remedy is to introduce GCMC with alchemical windows as a equilibration step before production.
Cholesterol/lipid binding in membrane proteins: Some membrane proteins bind cholesterol or other lipids in the apo state at lipid-exposed pockets, but this can be difficult to sample because lipid relaxation is slow and expensive. Coarse-grained MD could be used to probe cholesterol residence times, followed by a separate FEP leg to account for the apo-state contribution.
Ion binding in the apo state: Similar to lipids, ions can stabilize apo conformations or occupy relevant binding-site positions, and may require an additional sampling strategy or FEP correction.
Conformational rearrangement of the pocket or protein: This is likely the most challenging and common source of overestimation. Apo and holo states may differ significantly in binding-site geometry or protein conformation. Ensemble analysis and suitable collective variables, such as those used by Vogele et al., can help diagnose these differences. Once apo and holo states are identified, possible corrections include seeding later ABFE windows with apo-like structures or using umbrella-sampling-like methods to map the free-energy surface between apo and holo states.
This section would frame apo-state accessibility as a general limitation in ABFE workflows and summarize practical approaches for diagnosing and correcting it. The checklist in section 11 would be modified accordingly.
Issue description:
ABFEs can overestimate binding affinities when the apo state is not adequately sampled on accessible simulation timescales. This limitation shows up in several related ways and could be discussed either as a standalone section or distributed across the existing water-network, conformational sampling, and cofactor sections.
The main cases to cover are:
Water resolvation in occluded pockets: In some systems, water does not re-enter the binding site during non-interacting alchemical windows, which can bias ABFEs toward overestimation. A possible remedy is to introduce GCMC with alchemical windows as a equilibration step before production.
Cholesterol/lipid binding in membrane proteins: Some membrane proteins bind cholesterol or other lipids in the apo state at lipid-exposed pockets, but this can be difficult to sample because lipid relaxation is slow and expensive. Coarse-grained MD could be used to probe cholesterol residence times, followed by a separate FEP leg to account for the apo-state contribution.
Ion binding in the apo state: Similar to lipids, ions can stabilize apo conformations or occupy relevant binding-site positions, and may require an additional sampling strategy or FEP correction.
Conformational rearrangement of the pocket or protein: This is likely the most challenging and common source of overestimation. Apo and holo states may differ significantly in binding-site geometry or protein conformation. Ensemble analysis and suitable collective variables, such as those used by Vogele et al., can help diagnose these differences. Once apo and holo states are identified, possible corrections include seeding later ABFE windows with apo-like structures or using umbrella-sampling-like methods to map the free-energy surface between apo and holo states.
This section would frame apo-state accessibility as a general limitation in ABFE workflows and summarize practical approaches for diagnosing and correcting it. The checklist in section 11 would be modified accordingly.
Sorry for the delay @Nithishwer & @fjclark
Folks mention section 6.2 and 8, however a lot of it also exists in section 5.2.
Here's my rough review of where we currently are at:
Water sampling
As mentioned, the issues regarding water sampling are discussed in 6.2.2. We already discuss the need to use enhanced sampling methodologies to deal with this in that section.
Lipid binding
This is somewhat discussed in 5.2 under "membrane proteins require additional care". Specifically we mention the challenges associated with displacing lipids from the binding site.
Ion binding
I'm not immediately seeing anything - this could be something to add somewhere in cofactors or conserved binding waters in…